Clinical and Experimental Ophthalmology最新文献_第5页

Evaluation of ChatGPT-4 responses to glaucoma patients' questions: Can artificial intelligence become a trusted advisor between doctor and patient? 评估 ChatGPT-4 对青光眼患者问题的回答：人工智能能否成为医患之间值得信赖的顾问？

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-15 DOI: 10.1111/ceo.14451

Muzaffer Said Güler MD, Elif Ertan Baydemir MD

引用次数: 0

Comparison of intraocular pressure and anterior segment parameters in subjects with asymmetrical primary angle closure disease: Response 不对称原发性闭角病患者眼压和眼前节参数的比较：反应。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-15 DOI: 10.1111/ceo.14453

Shayne S. Tan MBBS, MRCS(Ed), Tin A. Tun MBBS, PhD, Monisha E. Nongpiur MD, PhD

引用次数: 0

Prediction of refraction error after toric lens implantation with biometric input data uncertainties and power labelling tolerances 利用生物统计学输入数据的不确定性和功率标签公差，预测散光晶体植入术后的屈光误差。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-09 DOI: 10.1111/ceo.14449

Achim Langenbucher PhD, Nóra Szentmáry MD, PhD, Alan Cayless PhD, David Cooke MD, PhD, Peter Hoffmann MD, Jascha Wendelstein MD, PhD

Background

The purpose of this study was to simulate the impact of biometric measure uncertainties, lens equivalent and toric power labelling tolerances and axis alignment errors on the refractive outcome after cataract surgery with toric lens implantation.

Methods

In this retrospective non-randomised cross sectional Monte-Carlo simulation study we evaluated a dataset containing 7458 LenStar 900 preoperative biometric measurements. The biometric uncertainties from literature, lens power labelling according to ISO 11979, and axis alignment tolerances of a modern toric lens (Hoya Vivinex) were taken to be normally distributed and used in a Monte-Carlo simulation with 100 000 samples per eye. The target variable was the defocus equivalent (DEQ) derived using the Castrop (DEQ_C) and the Haigis (DEQ_H) formulae.

Results

Mean/median / 90% quantile DEQ_C was 0.22/0.21/0.36 D and DEQ_H was 0.20/0.19/0.32 D. Ignoring the variation in lens power labelling and toric axis alignment the respective DEQ_C was 0.20/0.19/0.32 D and DEQ_H was 0.18/0.17/0.29 D. DEQ_C and DEQ_H increased with shorter eyes, steeper corneas, equivalent lens power and highly with toric lens power.

Conclusions

According to our simulation results, uncertainties in biometric measures, lens power labelling tolerances, and axis alignment errors are responsible for a significant part of the refraction prediction error after cataract surgery with toric lens implantation. Additional labelling of the exact equivalent and toric power on the lens package could be a step to improve postoperative results.

背景：本研究的目的是模拟生物测量不确定性、晶状体等效和散光功率标注公差以及轴对准误差对散光晶状体植入白内障手术后屈光结果的影响：在这项回顾性非随机横断面蒙特卡洛模拟研究中，我们评估了包含 7458 个 LenStar 900 术前生物测量数据集。文献中的生物测量不确定性、根据 ISO 11979 进行的镜片功率标注以及现代散光透镜（Hoya Vivinex）的轴对准公差均被视为正态分布，并用于每只眼睛 100 000 个样本的蒙特卡洛模拟。目标变量是使用卡斯特罗普（DEQC）和海吉斯（DEQH）公式得出的散焦当量（DEQ）：平均值/中值/90%量值 DEQC 为 0.22/0.21/0.36 D，DEQH 为 0.20/0.19/0.32 D。如果忽略镜片功率标记和散光轴对准的变化，DEQC分别为0.20/0.19/0.32 D，DEQH分别为0.18/0.17/0.29 D。DEQC和DEQH随着眼球变短、角膜变陡和等效镜片功率的增加而增加，随着散光镜片功率的增加而增加：根据我们的模拟结果，生物测量的不确定性、镜片功率标注公差和轴对齐误差是造成散光人工晶体植入白内障手术后屈光度预测误差的主要原因。在镜片包装上额外标注精确的等效和散光功率可能是改善术后效果的一个步骤。

{"title":"Prediction of refraction error after toric lens implantation with biometric input data uncertainties and power labelling tolerances","authors":"Achim Langenbucher PhD, Nóra Szentmáry MD, PhD, Alan Cayless PhD, David Cooke MD, PhD, Peter Hoffmann MD, Jascha Wendelstein MD, PhD","doi":"10.1111/ceo.14449","DOIUrl":"10.1111/ceo.14449","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The purpose of this study was to simulate the impact of biometric measure uncertainties, lens equivalent and toric power labelling tolerances and axis alignment errors on the refractive outcome after cataract surgery with toric lens implantation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this retrospective non-randomised cross sectional Monte-Carlo simulation study we evaluated a dataset containing 7458 LenStar 900 preoperative biometric measurements. The biometric uncertainties from literature, lens power labelling according to ISO 11979, and axis alignment tolerances of a modern toric lens (Hoya Vivinex) were taken to be normally distributed and used in a Monte-Carlo simulation with 100 000 samples per eye. The target variable was the defocus equivalent (DEQ) derived using the Castrop (DEQ<sub>C</sub>) and the Haigis (DEQ<sub>H</sub>) formulae.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean/median / 90% quantile DEQ<sub>C</sub> was 0.22/0.21/0.36 D and DEQ<sub>H</sub> was 0.20/0.19/0.32 D. Ignoring the variation in lens power labelling and toric axis alignment the respective DEQ<sub>C</sub> was 0.20/0.19/0.32 D and DEQ<sub>H</sub> was 0.18/0.17/0.29 D. DEQ<sub>C</sub> and DEQ<sub>H</sub> increased with shorter eyes, steeper corneas, equivalent lens power and highly with toric lens power.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>According to our simulation results, uncertainties in biometric measures, lens power labelling tolerances, and axis alignment errors are responsible for a significant part of the refraction prediction error after cataract surgery with toric lens implantation. Additional labelling of the exact equivalent and toric power on the lens package could be a step to improve postoperative results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"26-38"},"PeriodicalIF":4.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ceo.14449","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis 对长期控制正常张力青光眼的医疗方法进行比较分析：系统综述和基于模型的网络荟萃分析。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-09 DOI: 10.1111/ceo.14447

Ting-Kai Yang MD, Hou-Ting Kuo MD, Yuh-Jen Ju MD, Chun-Yi Chen MD, Wen-Hsien Chen MD, Albert Y. Wu MD, Chun-Ju Lin MD, Chien-Chang Lee MD, ScD, Jennifer Hui-Chun Ho MD, PhD

Background

To evaluate and compare the long-term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. ‘Long-term’ is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).

Methods

This systematic review and model-based network meta-analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs. Patients with NTG were selected based on strict inclusion/exclusion criteria, with randomsation procedures and masking as reported in the individual trials. Eight different medications were compared, including prostaglandin analogues, beta-blockers, brimonidine, unoprostone isopropyl, brovincamine, and palmitoylethanolamide (PEA). Notably, PEA is an oral medication, while other drugs are topical agents.

Results

Primary outcome is the long-term efficacy of IOP control across medications with different follow-up durations. Among the eight medications, PEA demonstrates the highest efficacy (Surface under the cumulative ranking, SUCRA = 7.46%), followed by two prostaglandin analogues: travoprost (SUCRA = 6.86%) and latanoprost (SUCRA = 6.76%), then two beta-blockers: nipradilol (SUCRA = 4.90%) and timolol (SUCRA = 4.89%). Both brimonidine and unoprostone isopropyl have SUCRA scores below 4.0%, indicating modest but limited efficacy. Brovincamine has the lowest SUCRA score (1.32%), reflecting minimal effectiveness.

Conclusions

This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG.

背景：评估和比较正常张力青光眼（NTG）药物治疗在控制眼压（IOP）方面的长期疗效，并根据疗效确定等级。在随机对照试验（RCTs）中，"长期 "是指治疗时间超过12周：这项系统性回顾和基于模型的网络荟萃分析（MBNMA）收集了随机对照试验中 795 名患者、997 只眼睛的数据。NTG患者是根据严格的纳入/排除标准筛选出来的，随机化程序和掩蔽方法与各试验报告一致。对八种不同的药物进行了比较，包括前列腺素类似物、β-受体阻滞剂、溴莫尼丁、异丙基异前列酮、溴辛胺和棕榈酰乙醇酰胺（PEA）。值得注意的是，PEA 是一种口服药物，而其他药物则是局部用药：主要结果是不同随访时间的药物对控制眼压的长期疗效。在八种药物中，PEA 的疗效最高（累积排名下的表面积，SUCRA = 7.46%），其次是两种前列腺素类似物：曲伏前列素（SUCRA = 6.86%）和拉坦前列素（SUCRA = 6.76%），然后是两种β-受体阻滞剂：尼普地洛（SUCRA = 4.90%）和噻吗洛尔（SUCRA = 4.89%）。溴莫尼定和异丙基 unoprostone 的 SUCRA 得分均低于 4.0%，表明疗效一般但有限。布洛芬卡明的 SUCRA 得分最低（1.32%），表明疗效甚微：本研究显示，PEA 是一种对 NTG 患者进行长期眼压控制很有前景的药物，有望用作主要或辅助治疗。研究结果要求在临床实践中考虑使用 PEA，并强调需要进一步研究其对 NTG 的长期疗效和安全性。

{"title":"Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis","authors":"Ting-Kai Yang MD, Hou-Ting Kuo MD, Yuh-Jen Ju MD, Chun-Yi Chen MD, Wen-Hsien Chen MD, Albert Y. Wu MD, Chun-Ju Lin MD, Chien-Chang Lee MD, ScD, Jennifer Hui-Chun Ho MD, PhD","doi":"10.1111/ceo.14447","DOIUrl":"10.1111/ceo.14447","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To evaluate and compare the long-term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. ‘Long-term’ is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This systematic review and model-based network meta-analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs. Patients with NTG were selected based on strict inclusion/exclusion criteria, with randomsation procedures and masking as reported in the individual trials. Eight different medications were compared, including prostaglandin analogues, beta-blockers, brimonidine, unoprostone isopropyl, brovincamine, and palmitoylethanolamide (PEA). Notably, PEA is an oral medication, while other drugs are topical agents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Primary outcome is the long-term efficacy of IOP control across medications with different follow-up durations. Among the eight medications, PEA demonstrates the highest efficacy (Surface under the cumulative ranking, SUCRA = 7.46%), followed by two prostaglandin analogues: travoprost (SUCRA = 6.86%) and latanoprost (SUCRA = 6.76%), then two beta-blockers: nipradilol (SUCRA = 4.90%) and timolol (SUCRA = 4.89%). Both brimonidine and unoprostone isopropyl have SUCRA scores below 4.0%, indicating modest but limited efficacy. Brovincamine has the lowest SUCRA score (1.32%), reflecting minimal effectiveness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"39-53"},"PeriodicalIF":4.9,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Continuing Professional Development 持续专业发展

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-08 DOI: 10.1111/ceo.14437

引用次数: 0

Antimicrobial stewardship in ocular infections: Fourteen years of over-the-counter chloramphenicol in Australia 眼部感染的抗菌药物管理：澳大利亚使用非处方氯霉素 14 年。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-08 DOI: 10.1111/ceo.14385

Christian P. Pappas MD, Maria Cabrera-Aguas MBBS, PhD, Stephanie L. Watson OAM, PhD, FRANZCO

引用次数: 0

Myopia and systemic manifestation of tissue hyperlaxity: A population-based cross-sectional study 近视与组织过度疏松的全身表现：一项基于人群的横断面研究。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-08 DOI: 10.1111/ceo.14450

Idan Hecht MD, Itay Nitzan MD, MPH, Margarita Safir MD

Background

Whether non-syndromic connective tissue hyperlaxity is associated with myopia is unknown. The aim of this study was to examine the association between systemic signs of tissue hyperlaxity and myopia among adolescents.

Methods

Included were adolescents assessed before mandatory military service at the age of 16–18 years between 2011 and 2022. Diagnoses of hernias, pes planus, genu varus, genu valgum, and scoliosis, as well as joint injuries were used as surrogate markers for tissue hyperlaxity. The prevalence of these events among adolescents with myopia was evaluated and compared to the non-myopic population.

Results

Included were 920 806 adolescents. The mean age was 17.4 ± 1.4 years and 58.6% were men. Myopia was diagnosed in 290 759 adolescents (31.6%) and high myopia in 24 069 adolescents (2.6%). The prevalence of hernias was higher among adolescents with myopia, (2.76%, 95% confidence interval (95% CI): 2.69%–2.82% vs. 2.60%, 95% CI: 2.57%–2.65%), as were pes planus (14.92%, 95% CI: 14.79–15.05 vs. 13.51%, 95% CI: 13.42–13.59) and scoliosis (9.14%, 95% CI: 9.03–9.24 vs. 7.69%, 95%CI: 7.62–7.76). The prevalence of joint injuries was clinically similar between groups (less than 0.1% difference for ankle, shoulder, and knee injuries), as were genu varum and genu valgum (0.66%, 95%CI: 0.64%–0.69% vs. 0.68%, 95% CI: 0.66–0.70, respectively). Adjusted for possible confounders results remained consistent.

Conclusions

Among a large sample of Israeli adolescents, those with myopia had a higher prevalence of hernias, pes planus, and scoliosis. These results could suggest a propensity for systemic conditions related to tissue laxity among myopic adolescents.

背景：非综合征结缔组织过度松弛是否与近视有关尚不清楚。本研究旨在探讨结缔组织过度松弛的全身症状与青少年近视之间的关联：研究对象为 2011 年至 2022 年间 16-18 岁的青少年，他们在服义务兵役前接受了评估。疝气、扁平足、足内翻、足外翻、脊柱侧弯以及关节损伤等诊断结果被用作组织过度松弛的替代标记。对患有近视的青少年中发生这些事件的比例进行了评估，并与非近视人群进行了比较：结果：共纳入 920 806 名青少年。平均年龄为 17.4 ± 1.4 岁，58.6% 为男性。290 759 名青少年（31.6%）被诊断为近视，24 069 名青少年（2.6%）被诊断为高度近视。疝气在近视青少年中的发病率较高（2.76%，95% 置信区间（95% CI）：2.69%-2.82% vs. 2.60%，95% CI：2.57%-2.65%）。65%），以及扁平足（14.92%，95% CI：14.79-15.05 vs. 13.51%，95% CI：13.42-13.59）和脊柱侧弯（9.14%，95% CI：9.03-9.24 vs. 7.69%，95%CI：7.62-7.76）。各组间关节损伤的发生率临床上相似（踝关节、肩关节和膝关节损伤的发生率相差不到 0.1%），而膝外翻和膝内翻的发生率也相似（分别为 0.66%，95%CI：0.64%-0.69% vs. 0.68%，95%CI：0.66-0.70）。对可能的混杂因素进行调整后，结果保持一致：在大量以色列青少年样本中，患有近视的青少年疝气、扁平足和脊柱侧弯的发病率较高。这些结果表明，近视青少年容易出现与组织松弛有关的全身性疾病。

{"title":"Myopia and systemic manifestation of tissue hyperlaxity: A population-based cross-sectional study","authors":"Idan Hecht MD, Itay Nitzan MD, MPH, Margarita Safir MD","doi":"10.1111/ceo.14450","DOIUrl":"10.1111/ceo.14450","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Whether non-syndromic connective tissue hyperlaxity is associated with myopia is unknown. The aim of this study was to examine the association between systemic signs of tissue hyperlaxity and myopia among adolescents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Included were adolescents assessed before mandatory military service at the age of 16–18 years between 2011 and 2022. Diagnoses of hernias, pes planus, genu varus, genu valgum, and scoliosis, as well as joint injuries were used as surrogate markers for tissue hyperlaxity. The prevalence of these events among adolescents with myopia was evaluated and compared to the non-myopic population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Included were 920 806 adolescents. The mean age was 17.4 ± 1.4 years and 58.6% were men. Myopia was diagnosed in 290 759 adolescents (31.6%) and high myopia in 24 069 adolescents (2.6%). The prevalence of hernias was higher among adolescents with myopia, (2.76%, 95% confidence interval (95% CI): 2.69%–2.82% vs. 2.60%, 95% CI: 2.57%–2.65%), as were pes planus (14.92%, 95% CI: 14.79–15.05 vs. 13.51%, 95% CI: 13.42–13.59) and scoliosis (9.14%, 95% CI: 9.03–9.24 vs. 7.69%, 95%CI: 7.62–7.76). The prevalence of joint injuries was clinically similar between groups (less than 0.1% difference for ankle, shoulder, and knee injuries), as were genu varum and genu valgum (0.66%, 95%CI: 0.64%–0.69% vs. 0.68%, 95% CI: 0.66–0.70, respectively). Adjusted for possible confounders results remained consistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among a large sample of Israeli adolescents, those with myopia had a higher prevalence of hernias, pes planus, and scoliosis. These results could suggest a propensity for systemic conditions related to tissue laxity among myopic adolescents.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"11-17"},"PeriodicalIF":4.9,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases. 根据癌症基因组图谱（TCGA）分类，按肿瘤大小分类的 1001 例葡萄膜黑色素瘤无转移生存率。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-04 DOI: 10.1111/ceo.14446

Rolika Bansal, Hidayet Sener, Arupa Ganguly, Jerry A Shields, Carol L Shields

Background: Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic-based, 4-category prognostic classification into Groups A-D). This study was conducted to assess impact on metastasis-free survival (MFS) in UM by tumour size category based on correlation with TCGA classification.

Methods: Retrospective analysis of 1001 cases categorised as small (0.0-3.0 mm), medium (3.1-8.0 mm) and large (≥8.1 mm), grouped by TCGA classification.

Results: Of 1001 cases, TCGA Groups (A/B/C/D) included small (n = 270, 75%/11%/13%/1%), medium (n = 503, 46%/14%/27%/13%) and large (n = 228, 23%/19%/38%/20%) UM. The 5-and 10-year Kaplan-Meier MFS for small UM revealed Group A (98%, 98%), Group B (100%, 100%), Group C (86%, NA) and Group D (100%, NA). For medium UM, the values dropped with Group A (95%, 93%), Group B (90%, 90%), Group C (68%, 38%), and Group D (44%, NA). For large UM, the values dropped further with Group A (94%, 86%), Group B (85%, NA), Group C (40%, 28%), and Group D (23%, NA). Additionally, a comparison (small vs. medium vs. large tumour size category) revealed TCGA low-risk grouping (Groups A or B) in 86% vs. 60% vs. 58% cases with UM.

Conclusion: By tumour size category, favourable cytogenetics (Groups A or B) is found in 86% of small tumours, 60% of medium tumours, and 58% of large tumours. The MFS at 10 years for favourable cytogenetics was 98% for small tumours, 92% for medium tumours, and 54% for large tumours. Tumour size category can serve as a surrogate for TCGA.

背景：葡萄膜黑色素瘤（UM）可按肿瘤大小类别和癌症基因组图谱（TCGA）组别（基于细胞遗传学的4类预后分类，分为A-D组）进行分类。本研究根据肿瘤大小类别与TCGA分类的相关性，评估无转移生存率（MFS）对UM的影响：方法：对1001例病例进行回顾性分析，按TCGA分类法分为小肿瘤（0.0-3.0毫米）、中肿瘤（3.1-8.0毫米）和大肿瘤（≥8.1毫米）：在1001个病例中，TCGA组（A/B/C/D）包括小型（n = 270，75%/11%/13%/1%）、中型（n = 503，46%/14%/27%/13%）和大型（n = 228，23%/19%/38%/20%）UM。小型 UM 的 5 年和 10 年 Kaplan-Meier MFS 显示，A 组（98%，98%）、B 组（100%，100%）、C 组（86%，NA）和 D 组（100%，NA）。中型 UM 的数值有所下降，A 组（95%，93%）、B 组（90%，90%）、C 组（68%，38%）和 D 组（44%，NA）。对于大型 UM，A 组（94%，86%）、B 组（85%，NA）、C 组（40%，28%）和 D 组（23%，NA）的数值进一步下降。此外，通过比较（小型肿瘤与中型肿瘤与大型肿瘤）发现，86%的 UM 病例与 60% 的 UM 病例与 58% 的 UM 病例属于 TCGA 低风险组（A 组或 B 组）：按肿瘤大小分类，86%的小型肿瘤、60%的中型肿瘤和58%的大型肿瘤的细胞遗传学状况良好（A组或B组）。细胞遗传学良好的小型肿瘤 10 年生存率为 98%，中型肿瘤为 92%，大型肿瘤为 54%。肿瘤大小类别可作为 TCGA 的替代指标。

{"title":"Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases.","authors":"Rolika Bansal, Hidayet Sener, Arupa Ganguly, Jerry A Shields, Carol L Shields","doi":"10.1111/ceo.14446","DOIUrl":"https://doi.org/10.1111/ceo.14446","url":null,"abstract":"<p><strong>Background: </strong>Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic-based, 4-category prognostic classification into Groups A-D). This study was conducted to assess impact on metastasis-free survival (MFS) in UM by tumour size category based on correlation with TCGA classification.</p><p><strong>Methods: </strong>Retrospective analysis of 1001 cases categorised as small (0.0-3.0 mm), medium (3.1-8.0 mm) and large (≥8.1 mm), grouped by TCGA classification.</p><p><strong>Results: </strong>Of 1001 cases, TCGA Groups (A/B/C/D) included small (n = 270, 75%/11%/13%/1%), medium (n = 503, 46%/14%/27%/13%) and large (n = 228, 23%/19%/38%/20%) UM. The 5-and 10-year Kaplan-Meier MFS for small UM revealed Group A (98%, 98%), Group B (100%, 100%), Group C (86%, NA) and Group D (100%, NA). For medium UM, the values dropped with Group A (95%, 93%), Group B (90%, 90%), Group C (68%, 38%), and Group D (44%, NA). For large UM, the values dropped further with Group A (94%, 86%), Group B (85%, NA), Group C (40%, 28%), and Group D (23%, NA). Additionally, a comparison (small vs. medium vs. large tumour size category) revealed TCGA low-risk grouping (Groups A or B) in 86% vs. 60% vs. 58% cases with UM.</p><p><strong>Conclusion: </strong>By tumour size category, favourable cytogenetics (Groups A or B) is found in 86% of small tumours, 60% of medium tumours, and 58% of large tumours. The MFS at 10 years for favourable cytogenetics was 98% for small tumours, 92% for medium tumours, and 54% for large tumours. Tumour size category can serve as a surrogate for TCGA.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of visual abnormalities detected through paediatric vision screening in Queensland, Australia 澳大利亚昆士兰州通过儿童视力筛查发现的视力异常患病率。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-03 DOI: 10.1111/ceo.14448

Ye Li MBChB, Shelley Duffy BNurs, Sagen Wilks BNurs, Rachel Keel BNurs, Rachael Beswick PhD, Shuan Dai FRANZCO

Background

Vision screening programs can provide epidemiological information regarding visual impairment in children. This study aims to report the characteristics of visual abnormalities diagnosed through the Primary School Nurse Health Readiness Program (PSNHRP) in Queensland, Australia.

Methods

A retrospective review of vision screening records from the PSNHRP between January 2017 and December 2020 was undertaken. Children aged between 4 and 7 who underwent vision screening were included for review. Children with a visual acuity of worse than 6/9–1 using the Parr 4 m letter-matching chart or those who failed the SPOT Vision Screener were referred to an optometrist or ophthalmologist for review.

Results

164 890 children underwent vision screening. 12148 children failed visual screening (7.4%) and were referred for an eye assessment. 6011 (69.4%) of the 8659 children who attended ophthalmic review had a confirmed visual abnormality. Of 164 890 screened children, 1187 (0.72%) were confirmed to have anisometropia, 3843 (2.33%) had refractive error, 194 (0.12%) had strabismus, 755 (0.46%) had anisometropic amblyopia, 136 (0.08%) had strabismic amblyopia, and 1356 (0.82%) had an unspecific abnormality. There was no statistically significant difference in the age at screening between any visual abnormality (p = 0.94). Anisometropia, refractive error, and strabismus were significantly more common in females than males (p = 0.03, p < 0.01, and p = 0.03 respectively), whereas anisometropic amblyopia was more common in males (p < 0.01).

Conclusions

We report the prevalence of visual abnormalities detected through the PSNHRP vision screening program. Identification of medical or socioeconomic risk factors that are likely to be associated with visual abnormalities can help to optimise vision screening programs.

背景：视力筛查计划可以提供有关儿童视力损伤的流行病学信息。本研究旨在报告澳大利亚昆士兰州通过小学护士健康准备计划（PSNHRP）诊断出的视力异常的特征：本研究对 2017 年 1 月至 2020 年 12 月期间 PSNHRP 的视力筛查记录进行了回顾性审查。接受视力筛查的儿童年龄在 4 至 7 岁之间。使用 Parr 4 m 字母配对表检测视力低于 6/9-1 或 SPOT 视力筛查未通过的儿童将被转介至验光师或眼科医生进行复查：164 890 名儿童接受了视力筛查。有 12148 名儿童（7.4%）未能通过视力筛查，并被转介接受眼科评估。在接受眼科复查的 8659 名儿童中，有 6011 名（69.4%）儿童的视力确有异常。在 164 890 名接受筛查的儿童中，有 1187 人（0.72%）被证实患有异视，3843 人（2.33%）患有屈光不正，194 人（0.12%）患有斜视，755 人（0.46%）患有异向性弱视，136 人（0.08%）患有斜视性弱视，1356 人（0.82%）患有不明异常。不同视力异常者的筛查年龄差异无统计学意义（P = 0.94）。女性患有斜视、屈光不正和斜视的比例明显高于男性（p = 0.03，p 结论：女性患有斜视、屈光不正和斜视的比例明显高于男性（p = 0.03，p 结论：女性患有斜视、屈光不正和斜视的比例明显高于男性（p = 0.03）：我们报告了通过 PSNHRP 视力筛查项目发现的视力异常的发生率。找出可能与视力异常有关的医疗或社会经济风险因素有助于优化视力筛查计划。

{"title":"Prevalence of visual abnormalities detected through paediatric vision screening in Queensland, Australia","authors":"Ye Li MBChB, Shelley Duffy BNurs, Sagen Wilks BNurs, Rachel Keel BNurs, Rachael Beswick PhD, Shuan Dai FRANZCO","doi":"10.1111/ceo.14448","DOIUrl":"10.1111/ceo.14448","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Vision screening programs can provide epidemiological information regarding visual impairment in children. This study aims to report the characteristics of visual abnormalities diagnosed through the Primary School Nurse Health Readiness Program (PSNHRP) in Queensland, Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review of vision screening records from the PSNHRP between January 2017 and December 2020 was undertaken. Children aged between 4 and 7 who underwent vision screening were included for review. Children with a visual acuity of worse than 6/9–1 using the Parr 4 m letter-matching chart or those who failed the SPOT Vision Screener were referred to an optometrist or ophthalmologist for review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>164 890 children underwent vision screening. 12148 children failed visual screening (7.4%) and were referred for an eye assessment. 6011 (69.4%) of the 8659 children who attended ophthalmic review had a confirmed visual abnormality. Of 164 890 screened children, 1187 (0.72%) were confirmed to have anisometropia, 3843 (2.33%) had refractive error, 194 (0.12%) had strabismus, 755 (0.46%) had anisometropic amblyopia, 136 (0.08%) had strabismic amblyopia, and 1356 (0.82%) had an unspecific abnormality. There was no statistically significant difference in the age at screening between any visual abnormality (<i>p</i> = 0.94). Anisometropia, refractive error, and strabismus were significantly more common in females than males (<i>p</i> = 0.03, <i>p</i> < 0.01, and <i>p</i> = 0.03 respectively), whereas anisometropic amblyopia was more common in males (<i>p</i> < 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We report the prevalence of visual abnormalities detected through the PSNHRP vision screening program. Identification of medical or socioeconomic risk factors that are likely to be associated with visual abnormalities can help to optimise vision screening programs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"18-25"},"PeriodicalIF":4.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ceo.14448","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reactivation of stable neovascular age-related macular degeneration following treat-and-extend regimen discontinuation 停止治疗和延长疗程后，稳定的新生血管性老年性黄斑变性再次激活。

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology

Pub Date : 2024-10-02 DOI: 10.1111/ceo.14444

Jose Carlo M. Artiaga MD, FICO, Shiao Wei Wong FRCOphth, Deepthy Menon MBBS, Swetha Kumar DO, DNB, Pankaja Dhoble MBBS, MS, Sridevi Thottarath MBBS, Luke Nicholson MD(Res), FRCOphth

Background

To describe the incidence and pattern of reactivation of neovascular age-related macular degeneration (nAMD) following successful treatment with treat-and-extend intravitreal anti-vascular endothelial growth factor therapy.

Methods

Consecutive patients with treated nAMD who did not require further treatment over a 6-month period and who attended their 3-monthly optical coherence tomography monitoring clinic in Moorfields Eye Hospital from 1 November 2019 to 31 January 2020 were included. Patients with diagnoses of macular neovascularization other than AMD, and patients with incomplete data were excluded. Baseline demographics recorded were age, sex, race, laterality, cause of macular neovascularization, drug, number of injections, and duration of treatment. Date, setting, symptoms, and time to retreatment were collected among patients with disease reactivation.

Results

The medical records of 286 patients were included. Most patients were female (64.3%), white (68.18%), and were receiving aflibercept monotherapy (55.2%). Mean number of injections at baseline was 17.79 ± 11.74 (range 3–62) with a mean treatment duration of 39.47 ± 30.68 months (range 2–139). Reactivation of AMD was identified in 32.2% of cases with 87% of recurrences identified via scheduled visit. The most common symptom was blurring of vision in 44.6%, while 39.1% were asymptomatic. Mean time from baseline to retreatment was 29.37 ± 22.40 months (range 5–104), with 20.7%, 73.9% and 88.04% of these patients requiring retreatment within 1, 3, and 5 years, respectively.

Conclusions

Despite prior treatment with no reactivation in 6 months, 32.2% reactivate, 73.9% of which within 3 years. A significant proportion, 39.1%, reactivated without symptoms necessitating regular monitoring in the first 5 years.

背景：目的：描述在成功接受玻璃体内抗血管内皮生长因子治疗（treat-and-extend intravitreal anti-vascular endothelial growth factor therapy）后，新生血管性年龄相关性黄斑变性（nAMD）再活化的发生率和模式：方法：纳入2019年11月1日至2020年1月31日期间在Moorfields眼科医院参加3个月一次的光学相干断层扫描监测门诊、在6个月内不需要进一步治疗的经治疗的nAMD患者。除 AMD 外，诊断为黄斑新生血管的患者和数据不完整的患者均被排除在外。记录的基线人口统计学数据包括年龄、性别、种族、侧位、黄斑新生血管的病因、药物、注射次数和治疗持续时间。在疾病再次复发的患者中，收集了再次治疗的日期、环境、症状和时间：结果：共收录了 286 名患者的病历。大多数患者为女性（64.3%）、白人（68.18%），接受阿弗利百普单药治疗（55.2%）。基线平均注射次数为 17.79 ± 11.74（范围 3-62）次，平均治疗时间为 39.47 ± 30.68 个月（范围 2-139）个月。在 32.2% 的病例中发现了 AMD 复发，其中 87% 的复发是通过预约就诊发现的。最常见的症状是视力模糊，占 44.6%，无症状的占 39.1%。从基线到再治疗的平均时间为 29.37 ± 22.40 个月（5-104 个月），其中 20.7%、73.9% 和 88.04% 的患者分别需要在 1 年、3 年和 5 年内进行再治疗：尽管之前的治疗在 6 个月内没有再次激活，但仍有 32.2% 的患者再次激活，其中 73.9% 的患者在 3 年内再次激活。39.1%的患者在没有症状的情况下再次感染，因此需要在最初的5年内进行定期监测。

{"title":"Reactivation of stable neovascular age-related macular degeneration following treat-and-extend regimen discontinuation","authors":"Jose Carlo M. Artiaga MD, FICO, Shiao Wei Wong FRCOphth, Deepthy Menon MBBS, Swetha Kumar DO, DNB, Pankaja Dhoble MBBS, MS, Sridevi Thottarath MBBS, Luke Nicholson MD(Res), FRCOphth","doi":"10.1111/ceo.14444","DOIUrl":"10.1111/ceo.14444","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To describe the incidence and pattern of reactivation of neovascular age-related macular degeneration (nAMD) following successful treatment with treat-and-extend intravitreal anti-vascular endothelial growth factor therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Consecutive patients with treated nAMD who did not require further treatment over a 6-month period and who attended their 3-monthly optical coherence tomography monitoring clinic in Moorfields Eye Hospital from 1 November 2019 to 31 January 2020 were included. Patients with diagnoses of macular neovascularization other than AMD, and patients with incomplete data were excluded. Baseline demographics recorded were age, sex, race, laterality, cause of macular neovascularization, drug, number of injections, and duration of treatment. Date, setting, symptoms, and time to retreatment were collected among patients with disease reactivation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The medical records of 286 patients were included. Most patients were female (64.3%), white (68.18%), and were receiving aflibercept monotherapy (55.2%). Mean number of injections at baseline was 17.79 ± 11.74 (range 3–62) with a mean treatment duration of 39.47 ± 30.68 months (range 2–139). Reactivation of AMD was identified in 32.2% of cases with 87% of recurrences identified via scheduled visit. The most common symptom was blurring of vision in 44.6%, while 39.1% were asymptomatic. Mean time from baseline to retreatment was 29.37 ± 22.40 months (range 5–104), with 20.7%, 73.9% and 88.04% of these patients requiring retreatment within 1, 3, and 5 years, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite prior treatment with no reactivation in 6 months, 32.2% reactivate, 73.9% of which within 3 years. A significant proportion, 39.1%, reactivated without symptoms necessitating regular monitoring in the first 5 years.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 1","pages":"76-83"},"PeriodicalIF":4.9,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0